一种叫作 Nedocromil 的抗哮喘新药去年在美国上市。它具有抗过敏及抗炎作用,其抑制乳突细胞分泌炎症介质的作用与色甘酸钠相似。据报道,其作用比色甘酸钠强,并能稳定释放炎症介质的其它类型细胞。与色甘酸钠一样,其予防哮喘发作的作用机制目前尚不十分明瞭。医学界的权威们越来越强烈地认为,仅靠用支气管扩张药来治疗哮喘是远不能令人满意的,他们需要有能在早期控制下气道炎症的药物,所以 A new anti-asthma drug called Nedocromil went on sale in the United States last year. It has anti-allergic and anti-inflammatory effects, and its inhibit papillary cells secretion of inflammatory mediators and cromolyn sodium similar role. It is reported that other types of cells that act more strongly than cromolyn and stably release inflammatory mediators. Like cromolyn, its mechanism of action to prevent asthma attacks is not yet clear. The authorities in the medical community are increasingly convinced that treatment of asthma alone with bronchodilators is far from satisfactory and require drugs that can control airway inflammation at an early stage,